The discovery of insulin almost 100 years ago has resulted in a remarkable increase in lifespan and quality of life for patients with type 1 diabetes. The Joslin Medalist Study has allowed researchers to access and study patients (Medalists) with type 1 diabetes who have been insulin dependent for 50 years or more. In this issue of the JCI, Yu et al. evaluated HLA variants, autoantibody status, beta cell function, C-peptide release, and monogenetic diabetes genes in a cohort of Medalists. Postmortem analysis of pancreata from Medalists revealed the presence of insulin-positive beta cells in these patients. Moreover, some patients were still able to respond to metabolic stimuli despite long-term insulin dependence. Overall, the Medalist cohort was highly heterogenous, and genetic testing suggested that several patients would fall into categories other than type 1 diabetes on the basis of REVEL (rare exome variant ensemble learner) classification and may be able to transfer to other therapy options.

Barbetti, F., Taylor, S.i. (2019). Insulin: Still a miracle after all these years. THE JOURNAL OF CLINICAL INVESTIGATION, 129(8), 3045-3047 [10.1172/JCI130310].

Insulin: Still a miracle after all these years

Barbetti F.;
2019-01-01

Abstract

The discovery of insulin almost 100 years ago has resulted in a remarkable increase in lifespan and quality of life for patients with type 1 diabetes. The Joslin Medalist Study has allowed researchers to access and study patients (Medalists) with type 1 diabetes who have been insulin dependent for 50 years or more. In this issue of the JCI, Yu et al. evaluated HLA variants, autoantibody status, beta cell function, C-peptide release, and monogenetic diabetes genes in a cohort of Medalists. Postmortem analysis of pancreata from Medalists revealed the presence of insulin-positive beta cells in these patients. Moreover, some patients were still able to respond to metabolic stimuli despite long-term insulin dependence. Overall, the Medalist cohort was highly heterogenous, and genetic testing suggested that several patients would fall into categories other than type 1 diabetes on the basis of REVEL (rare exome variant ensemble learner) classification and may be able to transfer to other therapy options.
2019
Pubblicato
Rilevanza internazionale
Commento
Esperti non anonimi
Settore MED/13 - ENDOCRINOLOGIA
English
Barbetti, F., Taylor, S.i. (2019). Insulin: Still a miracle after all these years. THE JOURNAL OF CLINICAL INVESTIGATION, 129(8), 3045-3047 [10.1172/JCI130310].
Barbetti, F; Taylor, Si
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
jci.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 1.59 MB
Formato Adobe PDF
1.59 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/237043
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 4
social impact